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ABSTRACT 
TITLE OF THE STUDY    To study the safety and efficacy of Mesenchymal Stromal Cells 
(MSC) in the treatment of recurrent high fistula-in-ano - A pilot study. 
DEPARTMENT: Surgery unit IV 
NAME OF CANDIDATE: Dr.  Zeeshan Rahman 
DEGREE AND SUBJECT:  MS (General Surgery) 
OBJECTIVES:  
- To assess the feasibility and safety of Mesenchymal stromal cells (MSC) as a 
treatment option for recurrent high fistula-in-ano. 
 
- To study the efficacy of Mesenchymal Stromal Cells (MSC) in the treatment of 
recurrent high fistula-in-ano. 
METHOD: 
Patients with recurrent high fistula-in-ano of crypto glandular origin (n = 7) underwent 
injection of heterologous Mesenchymal stromal cells (MSC), 40 million units into the 
fistula tract and were followed up for a total of 2 months. If healing was not detected 
clinically  at the end of 1 month,  the patients underwent a repeat injection of 
Mesenchymal stromal cells (MSC) into the fistula tract. All patients were followed up at 
the end of 2 months clinically and MRI was done for patients who had clinical healing 
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only. All patients were followed up for a duration of 4 months or till they were labeled 
as recurrence requiring another form of intervention. 
RESULTS: 
There were no adverse effects, reactions or worsening of primary disease  in all 7 
patients who underwent injections of Mesenchymal Stromal Cells (MSC) into the fistula 
tract. All patients were followed up for a period of 4 months and the procedure 
appeared to be safe, with no additional risk.  
At the end of 1 month fistula healing was observed in 4 out of 7 patients (57%) assessed 
clinically. Two patients had persistent fistula tracts and underwent a repeat sitting of 
MSC injection. At the end of 2 months 3 out of 7 (43%) patients had clinically healed 
fistula tracts  and at the end of 4 months 1 out of 7 patients had clinically healed. 
Imaging done at 2 months following procedure revealed persistence of the fluid filled 
fistula tract in all the patients. 
CONCLUSION:   
The injection of heterologous Mesenchymal Stromal Cells (MSC) in the treatment of 
chronic non-healing crypto glandular fistula-in-ano appeared to be safe. However it  did 
not heal the fistula tracts in this pilot study. 
KEYWORD: 
Mesenchymal Stromal Cells (MSC), Recurrent high fistula-in-ano, Cryptoglandular. 
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AIM AND OBJECTIVES 
 
Aim: To study the effect of Mesenchymal stromal cells (MSC) in the treatment of recurrent high 
fistula-in-ano. 
 
 
Objectives:  
 To assess the feasibility and safety of Mesenchymal Stromal Cells (MSC) as a treatment 
option for recurrent high fistula-in-ano. 
 
 To assess the effectiveness of Mesenchymal Stromal cells (MSC) in healing of   
recurrent high fistula-in-ano.
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Introduction 
Fistula-in-ano is defined as an abnormal communication between two epithelium lined 
surfaces.  It usually has an external opening on the skin of the perianal / perineal region 
and an internal opening at the ano-rectal junction.  
References to fistula-in-ano dates back to more than 2000 years back. Hippocrates, in 
420 BC had made references to the surgical therapy of fistula-in-ano and was the first 
person to advocate the use of setons (from the Latin seta, a bristle) in the treatment of 
chronic fistula-in-ano. 
In 1376, English surgeon Dr. Ardene described fistulotomy and seton use in his 
publication Treatises of Fistula in ano; Hemorrhoids and Clysters. 
In the 19th and 20th centuries numerous prominent surgeons such as Goodsall and Miles, 
Thompson, Lockhart-Mummery and Milligan and Morgan had made substantial 
contribution to the methodology of treatment of fistula-in-ano. 
Since the progress of early times there has been little change in the understanding of 
pathophysiology of fistula-in-ano. There have been many techniques described to 
minimize recurrence rates and prevent incontinence. However, despite 2000 years of 
knowledge of the disease process, fistula-in-ano still remains a perplexing disease. 
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Most fistulas are thought to result from blocked anal glands present in the anal valves 
resulting in cryptoglandular infection, leading to formation of an abscess, adjacent to 
the ano-rectal tube.  These fistulae are a consequence of rupture of perianal abscesses.  
As the abscess cavity ruptures it creates a tract between the anal canal and the 
epithelial lining of the perineal skin. The abscess is considered an acute inflammatory 
event, whereas the fistula is a result of a chronic inflammation. 
Symptoms usually affect the quality of life significantly and can range from minor 
discomfort with hygiene problems to frank septicemia. 
Surgery is usually the treatment of choice for these patients with the aim of removal of 
infection, excision of the fistula tract and preventing recurrent or persistent disease 
while preserving continence. 
The treatment of the fistula-in-ano has been evolving over the past 30 years. Usually 
these fistulas were surgically drained with the belief that removal of focus of infection 
would result in healing of the tract.  
Specific medical therapy like Infliximab is indicated for fistulas arising as a result of 
Crohn’s disease.  
The surgical options include lay-open of the tract or insertion of a seton. This results in 
loss of quality of life and difficulty in activities of daily living. A patient has to undergo 
repeated operations to change the seton till it is low enough to remove. This requires 
recurrent visits & hospitalization, and escalates the cost of treatment. 
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Currently newer techniques such as injection of glue or anal fistula plugs have been 
used to treat fistula-in-ano. However the success rates of these procedures are 
moderate with high recurrence rates and are costly. 
Newer methods of surgical management of fistula-in-ano have been mentioned recently 
like mucosal advancement, Ligation of Fistula Tract (LIFT), Bio-LIFT. All have been found 
to have some success rate, with various recurrence rates. These can be practiced in 
specialized centers and when prostheic materials are used, it makes the treatment 
costly.  
 
It has been theorized that these Mesenchymal stromal cells (MSC) extracted from bone 
marrow/adipose tissue/placenta have the capability to differentiate into fibrogenic 
precursors leading to fibrosis of the non-healing fistula tract. These stromal cells also 
have the ability to suppress inflammation.   
 
As a pilot project to a larger trial we proposed to study the safety and efficacy of 
heterologous Mesenchymal stromal cells (MSC) in the healing of recurrent high fistulas. 
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Review of Literature 
Epidemiology: 
The true prevalence of fistula-in ano is unknown. The worldwide incidence of anal 
fistulas secondary to perianal abscess ranges from 26 – 38%(1 , 2). 
The incidence of fistula-in-ano associated with underlying Crohn’s disease is 6 in 
1,00,000 and for Ulcerative colitis is 8 in 1,00,000(3). This data is mostly from the 
western population. There have been no studies done in India to ascertain the true 
incidence of perianal fistulas. 
The mean age at presentation is usually 40 years. The age group ranges from 20 years to 
60 years(3). 
Males are twice more likely to develop fistulas as compared to females(4). 
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Etiology 
The most common etiology in development of perianal fistulas is the formation of  ano-
rectal abscess(2). 
Other causes of fistula-in-ano are: 
 Inflammatory bowel disease – Crohn’s disease: Fistulas associated with Crohn’s 
disease are deep with persistent non-healing tracts. These fistulas are associated 
with bowel symptoms related to inflammatory bowel disease. 
The incidence of fistulas in Crohn’s disease is as high as 17-50%(5). 
 
 Malignancy 
Carcinoma rectum is associated with perianal fistula formation in locally 
advanced disease process. However, the incidence is low. 
 
 Radiation proctitis 
Usually associated with radiation given to the pelvis for genitourinary or rectal 
malignancy(6).  
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 Rectal foreign body 
On insertion of rectal foreign body there is trauma to the mucosa and 
submucosa. With the presence of a foreign body there is superadded infection 
leading to a perianal abscess formation and fistula formation(7). 
 
 Actinomycosis       
Although very rare, there has been evidence of perianal actinomycosis infection 
in immunocompromised patients resulting in non-healing fistulas(8,9).                 
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Anatomy of Anal canal 
 
Figure 1: Anatomy of anal canal(10) 
  
This is a diagrammatic representation of the anal canal and rectum showing the 
anatomical details of the external and internal anal sphincter and the location of the 
anal glands. 
 
 
Rectum 
Anal canal 
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Relevant anatomy 
The external anal sphincter is a voluntary muscle belonging to the striated muscle type 
which has 3 components: submucosal, superficial and deep muscles. The deep 
component is continuous with the puborectalis muscle and forms the anorectal sling 
which is very well palpable on digital rectal examination (DRE). The internal anal 
sphincter is a smooth muscle which lies in the muscularis layer and is an extension of 
the circular muscles of the rectum. 
At around 2.5 cm from the anal verge there are anal valves forming the dentate line and 
this signifies the union of the proctodaeum and the stomodaeum at this point.  Most of 
the anal glands open in to the crypts of the anal valves. The blockage of these openings 
and the infection of the glands result in formation of perirectal abscess. After drainage 
of the abscess it leads to formation of a fistula-in-ano. 
Goodsall’s Rule 
This rule states that fistulas with external openings lying anterior to a plane passing 
transversely from 3 o’ clock to 9 o’ clock position through the centre of the anus follows 
a straight radial course to the dentate line. The fistulas with external openings posterior 
to this line usually follows a curved tract to the posterior midline. 
The long anterior fistula in an exception to the rule.(11) 
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Figure 2: Goodsall’s rule (12) 
Pathogenesis  
The formation of fistula-in-ano has been explained by the widely accepted 
Crytpoglandular theory which is responsible for 90 % of perianal sepsis. There are about 
8-10 anal crypt glands arranged circumferentially within the anal canal at the level of the 
dentate line in the inter-sphincteric plane. The ducts of these glands penetrate the 
internal sphincter and open at the crypts of the anal valves. The anal crypt glands get 
obstructed due to inspissated debris leading to infection within these glands and 
Posterior 
Anterior 
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formation of abscess. This suppuration follows the path of least resistance and drains 
into the perineal spaces presenting acutely as a perianal abscess. Anorectal abscess is an 
acute manifestation of this cryptoglandular infection and rupture of the abscess onto 
the perineal skin lead to formation of a fistula which leads to chronicity. 
In 10% of patients, the cause of sepsis varies from inflammatory bowel disease, fungal 
infection, trauma, neoplasm or tubercular infections. These fistulas are classified as 
secondary fistulas and are usually complex. 
Park’s classification 
The Parks, Hardcastle and Gordon classification (known as the Parks Classification) is the 
most clinically relevant classification for fistula-in-ano. The classification defines four 
types of presentations of fistula-in-ano resulting from cryptoglandular infections:  
 
Figure 3: Classification of fistula-in-ano(13) 
Inter-sphincteric 
fistula 
Trans-sphincteric 
 
 Supra-sphincteric  Extra-sphincteric 
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A – Intersphincteric fistulas: These fistulas begin at the anal verge and traverse the 
intersphincteric plane to end in the perianal skin. 
 It usually results from a perianal abscess. 
 Course: It begins at the dentate line due to blocked anal glands and tracks 
Common course - It begins at the dentate line and traverses the internal anal 
sphincter to reach the inter-sphincteric plane. It points to the skin by tracking 
along this and terminates in the perianal skin or perineum. 
 Usually is associated with severe perianal pain and swelling. 
 Incidence - 70% of anal fistulas. 
 Other possible tracts – There may be no perineal opening or it may have a high 
tract traversing the puborectalis muscles. 
B – Trans-sphincteric fistulas: These fistulas begin at the anal verge and traverses across 
both the internal and external anal sphincters. 
 It usually results from the tracking of ischiorectal fossa abscesses. 
 Course: It originates at the dentate line and traverses across both the internal 
and external anal sphincters to lead to the ischiorectal fossa and finally on the 
perianal skin. 
 Incidence - 25% of anal fistulas. 
 Other possible tracts – High tracts with blind opening may coexist with the main 
tract. 
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C – Suprasphincteric fistulas: These fistulas begin at the anal verge and traverse above 
the external and internal anal sphincters to reach the ischiorectal fossa 
 It usually results from a rupture of supralevator abscess. 
 Course - It originates at the dentate line and traverses the internal anal sphincter 
to reach the intersphincteric plane. In this plane the tract curves upwards to 
track superior to the puborectalis muscle and traverses it lateral to the external 
anal sphincter complex to reach the ischiorectal fossa and further till the perianal 
skin.   
 Incidence - 5% percent of anal fistulas 
 Other possible tracts – High blind tracts are a possibility. 
D – Extrasphincteric fistulas: These fistulas are very high fistulas traversing the sphincter 
apparatus including the levator ani and terminated in the overlying skin. 
 It arises from varied etiology ranging from Foreign body penetration of the 
rectum, Crohn’s disease, penetrating injuries of the perineum, pelvic 
inflammatory disease or carcinoma of rectum. 
 Course – It courses from the skin through the ischiorectal fossa and tracks 
further up through the levator muscles till the rectal wall all the while lying 
outside the sphincter mechanism.  
 Incidence - 1% of anal fistulas. 
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Diagnosis 
The diagnosis of fistula-in-ano is mainly clinical. A history of perianal abscess drainage 
followed by persistent discharge from the perineum is highly suggestive of a fistula. A 
physical examination is the cornerstone of diagnosis. The entire perineum should be 
examined by the examiner to look for external opening as an opening or an elevated 
area of granulation tissue. There may be spontaneous discharge of blood or pus from 
the external opening which may be apparent on a digital rectal examination. 
A proctoscopic examination may show the internal opening. However, many a times it 
may not be identifiable, if the fistula in not active. It also indicates if the rectum is 
diseased with an underlying pathology such as Inflammatory bowel disease / 
Malignancy. 
Radiological Imaging  
Usually radiological imaging is not required for the diagnosis of fistula-in-ano. However 
if the diagnosis is not clear or it is a complex fistula radiologic imaging is helpful. Many a 
times, especially in recurrent fistula-in-ano it is used as a roadmap for planning of 
surgical procedure. There are several imaging modalities available and the efficacy of 
each is reviewed.  
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1. Fistulography 
This involves injection of iodinated contrast via the external opening followed by taking 
radiographic images in antero-posterior, lateral and oblique views to delineate the 
course of the tract and its opening into the anorectum. 
It was used as a diagnostic test in the past but currently is not in use. 
Its accuracy rate has been questioned and it ranges from 16-48%(14).  
Due to various limitations, fistulography is usually done in cases in which there is a 
suspicion of fistulous connection between the rectum and urinary bladder or vagina. 
 
2. Endoanal / endorectal ultrasonography 
This procedure involves passing a 7 – 10 Mhz ultrasound transducer into the anal canal 
to delineate the anatomy and differentiating intersphincteric from transsphincteric 
lesions. A balloon transducer is used to evaluate for extension of the fistula tract above 
the levator ani. 
Addition of hydrogen peroxide has been shown to be beneficial in outlining the fistula 
tract course and helps in identifying missed internal openings. 
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This modality has been reported to be 50% more efficacious in comparison to physical 
examination alone in evaluating the tract and planning for treatment(15). 
3. CT scan 
Computed tomography scans have not been shown to be very helpful in fistula-in-ano. It 
is not accurate in delineating soft tissue anatomy. It appears to be more helpful in the 
setting of inflammatory disease of the rectum as it is good in delineating fluid pockets. It 
also not popular because of its invasive nature and use of intravenous contrast which is 
associated with side-effects such as contrast induced nephropathy. 
4. MRI 
MRI is one of the most sensitive and specific investigation modality to evaluate for 
fistula-in-ano. It has shown 80-90 % concordance with operative findings. 
Dynamic contrast MRI has shown a sensitivity of 97% and a specificity of 100%. Hence it 
has become the investigation of choice when evaluating for complex, recurrent fistula-
in-ano. It also has shown to provide additional information regarding other secondary 
tracts and procedures which deal with it  have shown to reduce recurrence rates(16). 
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TREATMENT OF FISTULA-IN-ANO 
SIMPLE FISTULA 
Usually simple fistulas are low lying i.e. below the puborectalis sling.  The treatment 
options for low fistula-in-ano include the following: 
(1) Fistulotomy 
It involves laying open of fistula tract. A probe is passed from the external to 
the internal opening and the tract is laid open. In these patients partial 
division of internal sphincter does not affect the continence mechanism. 
 
 
Figure 4: Technique of Fistulotomy ( A – C) and Fistulectomy (D – G) (14) 
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(2) Fistulectomy 
In this procedure a probe is passed from the external opening into the internal 
opening demarcating the entire tract. A key hole skin incision is made over the 
external opening which is deepened through the subcutaneous tissue and the entire 
tract is excised from the surrounding tissue. Towards the internal opening the anal 
musculature is divided. In comparison to fistulotomy, a fistulectomy results in longer 
wound healing time. The incidence of anal incontinence was almost the same in 
both procedure as shown in numerous trials(17). 
 
(3) Fibrin glue 
Fibrin glue is a combination of fibrinogen and thrombin along with other clotting 
factors (Ca, Factor XIII and Apoprotein), which on combining lead to formation of a 
gel like clot which obliterates the tract. It is a non-operative intervention which is 
associated with low incontinence rates. It is a simple day care procedure which does 
not require hospitalization and the loss of job hours. Its failure does not complicate 
further management of the fistula-in-ano. It has been used with good efficacy in 
primary, single tract fistulas and low lying fistula-in-ano(18). 
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HIGH FISTULA-IN-ANO 
In patients with high fistula the tracts extend above the puborectal sling and hence 
encase a large mass of anal sphincter complex. The risk of incontinence in these patients 
following lay open of the fistula tract is very high.  Surgical options for these patients 
include: 
(1) Seton placement 
Setons are an option for treatment of high trans-sphincteric fistula in patients with very 
high probability of incontinence following surgery. The materials used as setons are non 
absorbable material like prolene, penrose drains, rubber bands, vessel loops and silastic 
catheters(19). 
There are two types of setons used for management of fistula-in-ano. 
The cutting type of setons incise through tissue while the non-cutting type of setons 
facilitate drainage of the fistula tract.  
Non-cutting setons were mainly used for patients in chronic sepsis and chronic diseases 
like HIV positive patients. Currently setons are used in combination with fistulotomy as a 
staged procedure. 
In Christian Medical College Hospital, Vellore Infant feeding tubes (# 6 or # 8) is used as 
setons. 
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The indications for use of setons are: 
- Complex fistula in ano 
- Recurrent fistula in ano 
- Anterior fistula in female patients 
- Patients with Crohn’s disease 
Setons can be used in 2 ways: 
(i) Single stage seton: 
The seton is tightened across the external and internal opening and is secured with a silk 
tie. The seton is pulled over 6-8 weeks and results in gradual descent of the seton with 
fibrosis and healing of the fistula tract. 
(ii) Two staged seton:  
The seton is passed around the deep portion of the external anal sphincter after 
opening the skin, subcutaneous tissue, internal anal sphincter and subcutaneous 
external anal sphincter. The seton is left loose to drain the inter-sphincteric space and 
promotes fibrosis unlike the cutting seton. Once the superficial wound heals the muscle 
component encompassed by the seton is divided making sure there is adequate 
sphincter muscle remaining to not adversely affect continence. 
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Figure 5 : Relation of sphincter muscles to seton(12) 
 
 
 
 
IS – Internal anal sphincter 
PR – Puborectalis sling 
D – Deep external anal sphincter  
SF – Superficial external anal 
sphincter 
SM – Submucosal external anal 
sphincter 
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(2)Mucosal advancement flap   
This technique is used for patients with high fistula in ano. The entire fistula is excised as 
a fistulectomy and the internal opening is sutured and covered using a mucosal flap 
from the adjacent mucosa with a base usually twice the apex of the flap. It is also known 
as the House advancement flap. The mucosal advancement flap is indicated in patients 
with high fistula-in-ano. The advantages of the procedure include a one stage procedure 
not requiring repeated hospitalization (as needed when seton is inserted). 
The internal opening is sutured using absorbable suture material and the mucosal flap is 
covered onto the internal opening after raising it as a tongue shaped flap which is 
sutured over the internal opening using absorbable sutures. 
It does not give good results with Crohn’s disease or in the setting of acute infection. 
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Figure 6 : Technique of Mucosal advancement flap(20) 
A- Passage of seton through the rectovaginal fistula 
B- Mucosal flap raised in the rectum 
C, D – Sutured mucosal flap after advancement – covering the internal opening. 
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 (3) LIFT procedure   
Ligation of Intersphincteric Fistula Tract (LIFT) is a technique used to treat high 
transsphincteric fistula in ano. The intersphincteric tract is identified and isolated. The 
entire tract from the external opening till the internal opening is excised after ligating it 
at the internal opening. The external anal sphincter is sutured using absorbable sutures 
and the fistula tract is excised.  This technique has the added advantage of not affecting 
continence as the external sphincter mechanism is not disturbed in this procedure. The 
technique was founded by Dr. Arjun Rojanasakul in 2007 and he reported a preliminary 
healing rate of 97%(21). 
A small incision is made at the anal verge after delineation of the tract using fistula 
probe. The inter-sphincteric plane is dissected and the fistula tract is identified by 
careful dissection. The tract is then hooked using a right angled clamp and the tract is 
ligated at the internal anal sphincter. Following this hydrogen peroxide is injected 
through the external opening to make sure the right tract was identified and divided. 
The external opening is then curetted with the remnant of the fistula tract till the inter-
sphincteric plane. The inter-sphincteric incision is sutured loosely. 
In a systematic review of studies the overall success rate of LIFT procedure ranged from 
40 – 95% with a pooled success rate of 71%. It appeared to be an effective sphincter 
preserving approach for treatment of trans-sphincteric fistula-in-ano(22). 
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Figure 7 : Technique of LIFT 
A – Identifying the internal opening                   B – Incision around the anal canal 
C – Identification of the fistula tract                    D – Suture ligation of the fistula tract 
A B 
C D 
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Various studies have compared the results of anorectal advancement flap technique to 
the technique of ligation of inter-sphincteric fistula tract (LIFT) which reveal almost 
similar efficacy and recurrence rates. The LIFT procedure is associated with more 
postoperative pain compared to mucosal advancement flap(23). 
 
(3) Adhesives  
These are relatively new tissue adhesive materials used as plugs. They are less invasive 
and carry less postoperative morbidity, e.g. Fibrin. These materials are used to plug the 
fistula tract. They are associated with very high recurrence rates as the tract is not dealt 
with and these measures only close the external opening temporarily. They are effective 
in management of simple fistula-in-ano with low lying tracts but are not as effective in 
high fistula-in-ano(18). 
 
(4) Anal fistula plugs 
These are plugs made from lyophilized porcine small intestine submucosa shaped in a 
conical fashion. These plugs are inserted into the fistula tract and obliterate the cavity.  
It has shown mixed results in various trials conducted worldwide and further research is 
warranted into this field (24–26). 
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Newer therapies 
Mesenchymal stromal cells (MSC) 
Adult stem cells have been shown to be useful in a number of areas of medical field. 
These stem cells can be derived from bone-marrow or adipose tissue – either 
autologous or heterologous and are considered to be multipotent. These cells replicate 
as undifferentiated cells and have the ability to differentiate into lineages of 
mesenchymal tissue including cartilage, fat, tendon, muscles and cartilage stroma. They 
are termed as Mesenchymal stromal cells (MSC). 
Due to their ability to alter both innate and adaptive immune response in individuals as 
well as their lack of immunogenicity they are considered to be a potent tool in 
regenerative cell therapy in autogenic as well as allogenic setting. 
They have been used in various phase I/II clinical trials with striking results. The most 
successful example of their use is in Steroid-refractory graft versus host disease. There 
have been no adverse effects reported after injections of these Mesenchymal stromal 
cells (MSCs) proving their safety and efficacy in clinical use.  
In the setting of inflammatory bowel disease these cells have been administered 
intraperitoneally (27), intravenously (28) or directly into the colon surrounding the 
mucosal defects (29) which has proven to be of benefit in rat experimental models. In 
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humans intra-fistular injections of adipose derived mesenchymal stromal cells have 
been safely employed in the setting of Crohn’s disease with success. These serial intra-
fistular injections have proven efficacy in treating complex perianal fistulas of 
cryptoglandular origin as well as those associated with Crohn’s disease.(30–33) 
In chronic non-healing fistulas these Mesenchymal stromal cells affect wound healing by 
2 mechanisms: 
(1) It can differentiate into fibrogenic precursors and result in fibrosis and 
healing of the active fistula tract 
(2) It has an anti-inflammatory action as it dampens the systemic inflammatory 
response  
These mesenchymal stromal cells are isolated after extraction from the bone marrow 
aspirate of the donor after removal of the other cell lines and expanded in vitro.  These 
cells maintain the potential to differentiate into fibrogenic precursors and have the 
capability to regenerate tissue damage and reduce inflammation and cause fibrosis. 
These cells are non-immunogenic as has been proved by various trials and can be safely 
transplanted in recipients as allogenic or autogenic ways. 
Here we present a phase II clinical trial that investigates the safety and efficacy of 
heterologous Mesenchymal Stromal Cells (MSC) as a stem cell based therapy in the 
treatment of recurrent trans-sphincteric/ supra-sphincteric fistulas of cryptoglandular 
type. We have preferred the use of bone marrow derived Mesenchymal stromal cells as 
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their genetic stability has been assessed using conventional methods as well as 
molecular karyotyping. 
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MATERIAL AND METHODS 
This was a  prospective,  non-randomized, interventional  study conducted  in  the  
Department  of  General  Surgery, Unit IV, at Christian  Medical  College  and  Hospital,  
Vellore  from   the  1st  of August 2012  to 1st September 2014   after  obtaining   
appropriate  approval  from  the  Institutional  Review  Board. 
Patient selection 
Patients were chosen for the study as per the following:  
Inclusion criteria 
      Patients included in the study had to meet the following criteria. 
- Age above the age of 18 years 
- Patients with cryptoglandular fistula-in-ano 
- Recurrent fistula-in-ano (Failure of at least 2 surgeries is considered as recurrence)  
- Trans-sphincteric / Supra-sphincteric fistulas 
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Exclusion criteria  
      Patients with the following presentations were excluded from the study: 
- Simple low fistula-in-ano 
 
- Fistulae with underlying malignancy / post radiation / IBD. 
 
 - Complex fistula-in-ano with involvement of bladder, vagina and other viscera. 
 
Sample size 
A total of 7 patients were enrolled in this study after obtaining prior informed consent 
as well as consent for photography from the duration of December 2012 till August 
2014. 
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ISOLATION OF 
MESENCHYMAL STROMAL 
CELLS (MSC’s)
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Isolation of Mesenchymal stromal cells 
 
Bone marrow was harvested from each patient after informed consent and screening of 
patients. MSCs were prepared as described below:   
The bone marrow (BM) aspirate was harvested under aseptic conditions. After checking 
the donor information (attached to the bone marrow aspirate container) with the donor 
information on the request and sampling of the BM aspirate at the Stem Cell 
Laboratory, sequential activities are performed in a clean room of the Good 
manufacturing practice facility in CMC leading to a qualified good manufacturing 
product that is administered to a patient.  The product leaves the Good manufacturing 
practice facility in CMC as a closed system (Cryopreservation Bag) cell suspension to 
which DMSO-containing cryopreservation mix is added at the Stem Cell Laboratory, 
where also the actual cryopreservation takes place as well as the preparation for 
administration after cryopreservation is done. 
 
 
The following reagents are used for expansion of Mesenchymal stromal cells in the stem 
cell research centre in Christian Medical College. 
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Table 1: Reagents used by stem cell laboratory 
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The following materials were used in expansion of these Mesenchymal Stromal cells 
(MSC). 
Table 1: Materials used in stem cell centre for isolation of Mesenchymal Stromal Cells 
(MSC) 
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Table 3: Materials used in isolation of Mesenchymal Stromal cells (MSC). 
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Sampling and Counting 
 
The sample and the necessary reagents were placed in the safety box after wiping them 
with 70% ethanol. The clothes are changed according to Good Manufacturing protocol 
before entering the clean room.  The Laminar air flow safety cabinet was disinfected and 
the UV lamp was switched on for 15 minutes. All products for use were placed in the 
laminar air flow safety cabinet. We took 0.5ml of Bone marrow aspirate for cell counting 
and the net bone marrow volume was determined. The Total white cell count was 
determined using the Sysmex counter.  
 
Preparation of density gradient 
 
The bone marrow sample was layered over a volume of sterile Ficoll-Paque (2:1 ratio 
respectively) in a sterile tube and the tube was spun at 400g for 30 minutes with 
medium acceleration and deceleration. The interface was collected using a sterile 
pipette into a new tube. This supernatant was washed using sterile phosphate buffered 
saline and centrifuged for 15 minutes at 700g with slow acceleration / deceleration 
twice. The pellet then is re-suspended into 10ml of Mesenchymal stromal cell culture 
medium and 0.1ml of sample was obtained for cell counting and viability assessment 
using Sysmex and trypan blue. 
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Preparation of culture medium  
 
The amount of MSC culture medium needed is calculated (12 ml / 11.25 x 106 cells) and 
then prepared using the below mentioned reagents.  
 
(1) Fetal Bovine Serum  
 
Commercially available Fetal Bovine serum (Refer SCRL – 008, section 4.1) is stored at -
20ºC as 50 ml aliquots in sterile centrifuge tubes and. The aliquots are used after 
thawing the required volumes.  
 
(2)  L-Glutamine  
 
 Commercially available L-Glutamine is frozen at -20ºC as 5 ml aliquots which are used 
as per the volume required. This  
 
(3) Hydrocortisone  
 
Hydrocortisone powder (36.3 mg) is dissolved in 400μl absolute alcohol by vortexing at 
37ºC for 5 minutes. De-ionized water (9.6ml) is added to it. This solution is 10X in 
concentration and is stored at -20ºC.  
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The working solution is prepared by mixing 1ml of the above stock solution with 9 ml 
distilled water, which is good for 30 days at 4ºC.  
 
 
(4)  2-Mercaptoethanol  
 
0.7 ml of 99% 2-mercaptoethanol is made up to 100 ml with de-ionized water. This is 
filtered under sterile conditions and stored as 0.5 ml aliquots at -20ºC 
 
(5) Penicillin/Streptomycin  
 
Commercially available Penicillin-Streptomycin solution (is stored at -20ºC as 0.5 ml 
aliquots. 
All the components required for the preparation of the MSC culture medium that are 
frozen are thawed by placing them either at 4ºC (refrigerator) overnight or at 37ºC in a 
water bath if they are to be used the same day. The above thawed components and 
Alpha MEM is taken into the CR by placing them in the pass box after cleaning their 
containers with 70% ethanol.  
0.5 ml Penicillin/Streptomycin, 50 ml of Fetal Bovine Serum, 5 ml of L-glutamate (100X), 
0.5 ml of 2-mercaptoetanol, 0.5ml of Hydrocortisone and 445 ml Minimal Essential 
Medium-Alpha is mixed together and filtered and plated to prepare the culture 
medium. 
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Trypsinisation 
 
The amount of 0.05% Trypsin/EDTA needed is calculated and is added to the culture 
medium and incubated in a CO2 incubator for 5 minutes and is checked under the 
inverted microscope whether the cells have detached from the bottom of the flasks. 
Following this a cell count is done using a neubaur chamber and viability checked using 
Trypan blue. These cells are then re-plated through 3 passes. 
 
Cryopreservation 
 
Preparation of Cryoprotectant  
 
The cryoprotectant (Mixture of Dimethyl Sulfoxide, Human Serum Albumin and 
Plasmalyte A in the ratio 1:1:3 respectively) is prepared by chilling and the amount of 
Mesenchymal stromal cells are added along with the cryoprotectant in the cryo-bags. 
These bags are frozen till -90 degrees and are then transferred to storage. 
 
Preparation of Mesenchymal stromal cells for administration 
The cells are centrifuged at 700g for 15 minutes with slow acceleration and deceleration 
after thawing and resuspended in 5% human serum albumin in PlasmalyteA. 
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The cell suspension is transferred to the transfer bag(s) using syringe and needle after 
dilution as per required for the study 
 
 
Figure 8 : Preparation of Mesenchymal Stromal cells (MSC) extract. 
                            
 
Concentration of cells used 
The Mesenchymal stromal cells (MSC) were used in a concentration of 40 million cells 
diluted in 10 cc of normal saline prepared after thawing the cryoprecipitate. 
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The protocol of extraction of Mesenchymal stromal cells 
 
 
Table 2 : Schematic representation of protocol of extraction of Mesenchymal Stromal 
cells (MSC). 
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Pre-Surgical procedure 
All patients were explained the nature of study and an informed consent was obtained for 
procedure as well as photography.  
All patients underwent MRI scans of the pelvis to look for the extent of the tract and the 
presence of any collections. 
Preoperative blood investigations were done which included  
- Hb 
- Creatinine 
- Blood borne viral screen 
- Chest X-ray  
- ECG 
All patients received preoperative IV antibiotics:  Metronidazole and Ciprofloxacin given after 
induction of anaesthesia and before the commencement of procedure. 
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Injection of stromal cells 
All patients were given the injection of Mesenchymal stromal cells (MSC) under aseptic 
measures in the operation theatre. The following steps were followed for each case. 
(1) The Fistula tract was identified by locating the external opening and identifying the 
internal opening. 
(2)  Fistula tract was instilled with hydrogen peroxide on a syringe through the external 
opening and the internal opening was confirmed.  
(3) The tract was gently curreted 
(4) The internal opening was sutured using absorbable sutures (3-0 Vicryl). 
(5) A lumbar puncture needle was used and the Mesenchymal stromal cell (MSC), 40 million 
diluted into 10ml of normal saline was injected in to the wall of the tract, at the internal 
opening site and the whole tract outwards. 
(6) The external opening was enlarged 
(7) Gauze and pad used for dressing. 
 
The time between preparation of the inoculums and injection of the Mesenchymal stromal 
cells was less than 1 hour. 
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CLINICAL 
PHOTOGRAPHS
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Clinical photographs depicting methodology 
Step 1  
Curetting of the fistula tract. 
 
 
Figure 9 : Fistula tract being curetted. 
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Step 2 
Ligation of the internal opening 
The internal opening was identified after injection of hydrogen peroxide from the external 
opening and visualizing the point of entry of hydrogen peroxide into the anal canal. 
The internal opening was suture ligated using 3-0 vicryl. 
 
 
Figure 10:  Fistula tract internal opening is identified and sutured. 
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Step 3 
Injection of Mesenchymal stromal cells into fistula tract. 
The mesenchymal stromal cells in a concentration of 40 Million units diluted in 10 cc of normal 
saline are injected around the fistula tract after ligation of the internal opening. 
Injection of Mesenchymal stromal cells in and around the fistula tract is done using a Lumbar 
puncture needle loaded onto the 10 cc syringe. The injection is done in a clockwise manner 
making sure all the walls of the fistula tract are injected with the MSC. 
 
Figure 11: Injection of MSC into the fistula tract. 
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Procedure of injection of MSC 
 
 
Figure 12 : Procedure of injection of Mesenchymal Stromal Cells (MSC) into the fistula 
tract 
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Post-operative care 
        The patients were started on normal diet after the procedure. Postoperatively sitz bath was 
avoided. All patients were discharged the following day if the patients were tolerating orally, 
pain free and had passed flatus and stools. 
      
Histopathological analysis 
All patients had tissue from the fistula tract sent for histopathological analysis. 
Follow-up schedule 
- Patients were reviewed at 1 week, 1 month, 2 months and 6 months to assess healing of 
the fistula tract. 
- If healing had not occurred in the immediate postoperative period (after 4 weeks) the 
patient underwent a repeat injection of 40 Million units of Mesenchymal stromal cells 
(MSC). 
- At 2 months review, all patients were assessed clinically and/or by MRI to define the 
status of the fistulous tract as closed or open. 
Patient’s who clinically had shown no response to the treatment after 2 months were 
labeled as failed cases and MRI was not done for these cases. These patients were given 
the option of surgical repair of the fistula. 
 
A fistula is classified as open or closed according to the Fistula Drainage Assessment: 
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 OPEN FISTULA: 
1. Purulent material is expelled with gentle pressure 
2. External opening not completely epithelialized 
3. Active fistula tract. 
 
 
 CLOSED FISTULA 
1. A fistula remains closed for 2 consecutive visits (at least 4 weeks apart), with no 
discharge or opening. 
2. MRI shows fibrosis of the fistula tract with no collection after the end of treatment. 
3. The patients are to be followed up till the duration of 1 year either by visit or phone 
to assess the healing of the fistulous tract. 
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CLINICAL CASES
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Patient 1 
 
 
Figure 13: Clinical photograph before procedure 
Fistula tract – Before injection of Mesenchymal stromal cells 
Fistula tract- External opening at 11 o’ clock position 3cm from the anal verge and internal 
opening at 11 o’ clock 2 cm from the anal verge. 
The tract was radial with pus pointing at the external opening. 
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Pre-Procedure MRI 
 
 
Figure 14; MRI of the fistula tract prior to procedure 
Description of the fistula tract 
Single tract 
Inter-sphincteric 
Mid anal canal 
No inter-sphincteric, supralevator, ischiorectal collection 
Ext opening- Right anterior quadrant 
Internal opening – 12 o’ clock mid anal canal 
Table 3: Description of the fistula tract 
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Patient 1 
After 2 months of follow up 
 
 
Figure 15; Clinical photo after 2 months. 
 
Clinically- There was no healing of the fistula tract. 
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Post-procedure MRI 
 
Figure 16 : Post- procedure MRI 
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Table 4: Description of the fistula tract 
Description of the fistula tract 
Persistence of the fistula 
No fibrosis of the fistula tract 
T2 hyper intensity – Same as prior to procedure 
No new disease present 
 
 
Patient underwent examination under anaesthesia and laying open of fistula under anaesthesia. 
Intra-operative findings: 
External opening was present at 11 o’ clock 3 cm from the anal verge.  
Internal opening was present at 12 o’ clock 2 cm from the anal verge.
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Patient 2 
 
Figure 17:  Fistula tract before the injection of Mesenchymal stromal cells. 
 
Fistula tract - Scar on the left side of anal verge. Opening at 5 o'clock, 5 cm from the anal 
verge, on the scar. The tract was trans-sphincteric with no intersphincteric extension, 
and lined with granulation tissue. Rectal mucosa was normal. 
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Pre-Procedure MRI 
 
 
Figure 18 : Pre-Procedure MRI 
MRI coronal and sagittal cuts revealing the fluid filled fistula tract    (T1 and T2W 
images)
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Description of fistula tract on MRI 
Single tract 
Trans-sphincteric fistula-in-ano 
Mid anal canal 
No inter-sphincteric collection 
No Ischiorectal collection 
No supralevator collection 
External opening – Left posterior quadrant 
Internal opening – 6 o’ clock position mid anal canal. 
Table 5: Description of the fistula tract prior to procedure 
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Patient 2 
After 2 months of follow-up 
 
Figure 19: Appearance of the fistula tract on 2 months follow-up. 
Fistula in ano with internal opening at 6 o' clock position at the anal verge 
 External opening was at 5 o' clock position 4 cm from the anal verge.  
Discharge was present at internal opening and scar had healed by secondary intention 
but the fistula tract was patent. As the fistula tract was patent clinically after 2 months- 
MRI was NOT done. Patient underwent operative procedure. 
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Patient 3 
 
Figure 20: Fistula before the injection of Mesenchymal Stromal Cells (MSC). 
 
There was a high trans-sphincteric fistulous tract with external opening at 8'o clock 
position, 5 cm from the anal verge & an internal opening at 6'o clock position at the PR 
sling with scars of previous surgery present. 
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Pre-Procedure MRI 
 
 
 
Figure 21: MRI images revealing the active fistula tract. 
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Description of fistula tract 
Single tract 
Suprasphincteric fistula 
High anal canal 
Inter-sphincteric collection present 
Supra-levator collection present 
Ischiorectal collection present 
Ext. opening- Right posterior quadrant 
Int. opening- 6 o’ clock high anal canal 
Table 6: Description of fistula tract prior to procedure. 
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At 1 month 
Patient was detected to have a patent external opening and underwent a repeat 
injection of Mesenchymal stromal cell injection (40 Million units/mm3). 
 
Intra-operative findings: 
External opening was on the scar close to the anal verge. The internal opening was 
closed and not evident on probing and hydrogen peroxide infiltration. The tract was 
filled with granulation and there was a small collection. 
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Patient 3 
After 2 months of follow-up 
 
 
Figure 22: Appearance of fistula tract at 2 months of follow-up. 
Re-epithelialized external opening with white scab formation over the external opening 
of the fistula tract. 
However after 3 months the external opening was patent with breakdown of 
epithelialisation. Post-procedure MRI was not done as clinically the tract had recurred. 
He underwent examination under anaesthesia and seton insertion. 
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Patient 4 
 
 
                         Figure 23: Appearance of the fistula tract prior to procedure 
 
There was a 5 cm scar present at 9 o’ clock position. There was induration and 
fluctuation in the lateral end of the scar. Internal opening was at 6 o’ clock position just 
beyond the anal verge. 
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Pre-Procedure MRI 
 
Figure 24: MRI images revealing the active fistula tract 
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Description of the fistula tract 
Single tract 
Trans-sphincteric fistula 
High anal fistula 
No inter-sphincteric collection 
No supra-levator collection 
No Ischiorectal collection 
Ext. opening – Right posterior quad. Internal opening – 6 o’ clock  
Table 7: Description of the fistula tract 
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Patient 4 
After 2 months follow-up 
 
Table 8: Clinical appearance of the fistula tract 2 months following injection of 
Mesenchymal Stromal Cells (MSC). 
  
Clinical examination revealed a healed external opening. 
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Post-Procedure MRI 
 
Figure 25: MRI appearance of the fistula tract following procedure. 
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Description of fistula tract 
Persistent fistula after 2 months 
No evidence of fibrosis 
T-2 Hyperintensity same as prior to procedure 
No evidence of new disease 
 
Patient had recurrence of symptoms after 3 months. 
He underwent examination under anaesthesia and seton insertion. 
Intraoperative findings:  
There was an external opening at 7 o’ clock position about 6 cm from anal verge. 
Internal opening at 6 o’ clock position about 1cm from anal verge. There was no 
collection. 
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Patient 5 
 
 
Figure 26: Clinical photograph prior to injection of Mesenchymal Stromal Cells (MSC). 
 
Fistula-in-ano: A fistula in ano was noted with two external openings, one at 4'O' clock, 
4cms from the anal verge and another at 9'O'clock, 3 cm from the anal verge. The 
internal opening was at 6'O' clock position about 2cm from the anal verge. There was 
presence of serous discharge from the external openings. 
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Pre-procedure MRI 
 
 
 
Figure 27: MRI visualizing active fistula tracts. 
This patient was detected to have two tracts as seen in the MRI 
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Description of the tracts 
First tract – (Right sided) Second tract – (Left sided) 
Trans-sphincteric tract Trans-sphincteric tract 
High anal canal Mid anal canal 
No inter-sphincteric collection No inter-sphincteric collection 
No supra-levator collection No supra-levator collection 
Ischiorectal collection present No Ischiorectal collection  
External opening – Right posterior 
quadrant 
External opening – Left posterior quadrant 
Internal opening- 7 o’ clock high anal canal Internal opening- 4 o’ clock mid anal canal 
Table 9: Description of the fistula tracts prior to injection of Mesenchymal Stromal 
Cells (MSC). 
This patient underwent Mesenchymal stromal cell injection into both the fistula tracts 
and was followed up after 1 month and 2 months respectively. 
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Patient 5 
After 2 months of follow-up 
 
 
Figure 28: Clinical photograph on 2 months of follow-up. 
Clinically – Healed external opening at 2 months but on follow-up there was break down 
of epithelialisation of the external opening at 3 months. 
Recurrence of symptoms of perianal discharge at 3 months. 
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Post-Procedure MRI 
 
 
Figure 29: MRI appearance of fistula tract on 2 months of follow-up. 
In the MRI films the right sided tract shows complete fibrosis with no remnant collection 
in the right ischiorectal fossa- right sided tract healed completely. The left sided tract 
continued to be patent.
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Post-Procedure comparison of both tracts 
Right sided tract Left sided tract 
No persistence of tract Tract still persistent 
Tract fibrosed No fibrosis 
T2 hyper intensity absent Same as prior to procedure 
No new disease No new disease 
Table 10: Description of the fistula tracts at 2 months of follow-up 
The patient was asymptomatic for 3 months but had recurrence of symptoms and 
discharge following that. 
He underwent Examination under anaesthesia and partial lying open of fistula tract with 
insertion of seton. 
Operative findings were: 
External opening at 4 o clock position 
High internal opening at 6 o clock with a collection in fistula tract. 
The fistula on the right side was completely fibrosed. 
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Patient 6 
 
Figure 30: Clinical photograph of fistula tract prior to injection of Mesenchymal 
Stromal Cells (MSC). 
 
Fistula-in-ano: External opening was present at 8 o clock position 5cm away from anal 
verge and an internal opening was present at 6 o clock position 1cm from anal verge. 
There were no palpable mass felt. Sphincter tone was normal. 
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Pre-procedure MRI 
 
Figure 31: MRI of the fistula tract prior to procedure 
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Description of the fistula tract 
Single tract 
Supra-sphincteric 
High anal canal 
Inter-sphincteric collection present 
No Ischiorectal collection 
No Supra-levator collection 
Ext. opening – Right posterior quadrant;                                                            
 Internal opening 6 o’ clock mid anal canal 
Table 11: Description of the fistula tract 
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Patient 6 
After 2 months of follow-up 
 
 
Figure 32: Appearance of the fistula tract following procedure. 
After 2 months - – Clinically persistent tract- Internal opening felt as nodule. 
 External opening patent; Hence MRI was not done. 
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Patient 7 
 
 
Figure 33: Appearance of the fistula tract prior to procedure 
  
Clinical photograph 
Fistula-in-ano: external opening at 4 o' clock position about 5cms from the anal verge 
and an internal opening at 6 o' clock position about 2 cm from the anal verge. 
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Pre-Procedure MRI 
 
 
 
Figure 34: MRI of the fistula tract prior to procedure 
 
 
 
100 
 
Description of the fistula tract 
Trans-sphincteric tract 
Mid anal canal  
No inter-sphincteric collection/ No ischiorectal collection/ No supralevator extension 
 
External opening -  Left posterior Quadrant;  
 
Internal opening – 12 o’ clock mid anal canal. 
Table 12: Description of the fistula tract. 
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Patient 7 
After 2 months of follow-up 
 
Figure 35: Appearance of the fistula tract after the procedure 
Fistula-in-ano:  
External opening: There was fibrosis of the external opening with no further discharge 
from the fistula tract. Symptoms of perianal discomfort and discharge did not recur at 6 
months of follow-up.
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Post-Procedure MRI 
 
 
Figure 36: MRI of the tract following procedure 
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Description of the fistula tract 
Fistula tract – Persistent 
No evidence of fibrosis 
T2 hyper intensity – Increased in post-procedure MRI 
No evidence of new disease 
Table 13: Description of the fistula tract following procedure 
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RESULTS
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Results 
A total of seven patients were included in the study and underwent injection of 
Mesenchymal Stromal cell (Table 15). There were no patients who were excluded and 
no-one was lost to follow-up. All the seven patients had a diagnosed high crypto 
glandular fistula-in-ano clinically as well as radiologically (using MRI).  Each patient had 
undergone a minimum of 2 operations before being included in the study as a non-
healing fistula-in-ano. The entire patient group consented for the procedure as well as 
intraoperative photography.  
All patients had a pre-procedure MRI done to document the type of fistula tract and the 
extent of disease. This would also give us an idea of the extent of healing following the 
Mesenchymal Stromal Cells (MSC) injections when compared with post-procedure MRI. 
 
Mesenchymal Stromal Cells (MSC) obtained from consenting donors were 
cryopreserved and required to be thawed prior to injection of the fistula tracts. The 
timing between the thawing of the Mesenchymal stromal cells and injection into the 
fistula tracts was less than 1 hour on an average. 
 
Patients underwent a clinical examination under anaesthesia on table followed by 
injection of Mesenchymal Stromal Cells (MSC) into the fistula tract.  
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All seven patients were injected with the Mesenchymal stromal cells in a concentration 
of 40 million/mm3 diluted in 10 ml of normal saline. All patients were followed up after 
1 month to clinically assess for re-epithelialization of the external opening indicating 
closure of the tract. 
In four patients there was healing of the tract clinically with epithelialization of the 
external opening with no further discharge at the end of one month. These patients 
were not subjected to repeat injection of Mesenchymal Stromal Cells (MSC) into the 
fistula tract and were reviewed after another month.  
In two patients there was a patent external opening of the fistula with persistent 
discharge at the end of one month. These patients underwent a repeat injection of 
Mesenchymal Stromal Cells (MSC) (40 Million/mm3 diluted in 10cc normal saline) and 
were asked to review after another month.  
One patient did not review after 1 month and hence the need for a second sitting of 
Mesenchymal Stromal Cell (MSC) injection could not be assessed. 
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Figure 37 : Follow-up at the end of 1 month 
 
After 2 months 
At the end of two months, three patients continued to have epithelialization of the 
external opening and no further discharge from the tract.   
A total of four patients had persistent discharge from the fistula tract with no healing of 
the external opening. These patients were diagnosed to have recurrence on the basis of 
N = 7 
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clinical presentation and a repeat MRI was not done to assess healing of the fistula tract 
in three of the four patients. 
After 2 months  
 
Figure 38: Follow-up at the end of 2 months- Clinically 
 
There were 57% (4 out of 7) cases which appeared to have not healed whereas 43%(3 
out of 7)  cases still had epithelialisation of the fistula tract. 
N = 7 
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At 4 months of follow-up only one patient was found to have epithelialization of the 
external opening and the remaining six patients had a patent external opening with pus 
discharge. 
The patients were diagnosed to have recurrence following the injection of Mesenchymal 
Stromal Cells (MSC) and underwent operative intervention in the form of seton 
placement. 
A total of four patients underwent MRI scans to visualize the fistula tract following 
procedure. Of these patients one patient had 2 fistulas prior to procedure but on follow 
–up there was complete obliteration of one of the fistula tracts while the other tract 
continued to be patent and thus he was treated as a failure of procedure.  
Table 14:Final outcome 
No. of Patients At 1 month At 2 months At 4 months 
 Healed Not 
healed 
Healed  Not 
Healed 
Healed  Not 
Healed 
7 4 3 3 4 1 6 
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Table 15: Patient details 
 
Study patients 
 
 
Pt  Age Gender Type of fistula 
Clinical 
assessment 
(1month) 
Passage 
MSC 
(x 10^6) 
 After 2 
months 
Clinically 
After 2 
months 
Radiologically 
1 60 M Cryptoglandular Healed 1 40 
 
Not 
Recurred 
Recurred 
2 55 M Cryptoglandular 
No follow-
up 
1 40 
 
Recurred  
Single tract 
healed 
3 36 M Cryptoglandular Not healed 2 80 
 
Recurred Not done 
4 31 M Cryptoglandular Healed 1 40 
 
Recurred Recurred 
5 37 M Cryptoglandular Not healed 2 80 
 
Recurred Not done 
6 31 M Cryptoglandular Healed 1 40 
 
Not 
Recurred 
Not done 
7 41 M Crytpoglandular Healed 1 40 
 
Not 
Recurred 
Not done 
M= Male; Age= Years 
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Table 16: On long term follow-up 
Patient  
At 1 month 
Follow-up 
At 2 months 
 
At 4 months 
Regular 
Surgery 
1 Healed Healed Not recurred  Not Required 
2 Healed  Recurred   xxxxxxxx Required 
3 Not healed Recurred xxxxxxxx Required 
4 Healed Recurred xxxxxxx Required 
5 Not healed Recurred xxxxxxx Required 
6 Healed Healed Recurred  Required 
7 Healed Healed Recurred  Required 
 
All the patients who were operated upon showed no evidence of adverse reactions to 
the injection of the Mesenchymal stromal cells. 
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Data from results 
Age distribution: 
 
Figure 39: Age distribution 
 
X- axis: Patients 
Y-axis: Age in years 
The oldest patient was 60 years old and the youngest patient was 31 years old. The 
mean age group of patients was 41 years. 
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Comorbid Illnesses 
 
 
Figure 40: Co-morbid illnesses of patients included in the study. 
 
There was one patient diagnosed to have Diabetes Mellitus and Carcinoma of urinary 
bladder who underwent transurethral resection of bladder tumor. 
There were two patients diagnosed to have systemic hypertension and were on 
medication. 
 
N = 7 
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Types of fistulas 
 
 
Figure 41: Types of fistulas 
On Imaging : 
The types of fistulas encountered were: 
Trans-sphincteric fistulas – 4 
Supra-sphincteric – 2 
Inter-sphincteric – 1 
 
N=7 
(4/7) (2/7) 
(1/7) 
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Relation to anal canal (High/Mid)  
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Figure 42: Relation of the fistula to anal canal 
There were a total of seven patients who underwent the procedure of Mesenchymal 
Stromal Cell (MSC) injection and one patient had 2 separate fistula tracts. 
 
 
 
 
N = 7 
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Hence out of a total of 7 fistulas: 
- 4 fistulas were opening into high anal canal  
- 3 fistulas were opening into mid anal canal 
 
 
Pathological diagnosis 
All patients underwent curettage of the fistula tract which was sent for biopsy. 
Histopathology revealed all fistulas to have chronic nonspecific inflammatory 
granulation tissue. 
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DISCUSSION
118 
 
Discussion 
In various studies done as phase I and phase II trials worldwide the technique of 
injection of mesenchymal stromal cells have shown promise in the treatment of non-
healing fistula-in-ano. Most of the studies have been done in patients with Crohn’s 
disease who had fistula-in-ano which was not amenable to medical or surgical therapy. 
 
Treatment of non-healing fistulas with surgery has been associated with high morbidity 
of repeated sittings of surgery as well as high recurrence rates. The patient often is in 
considerable distress due to insertion of a seton into the fistula tract. It affects the 
activities of daily living causing social handicap. Such patients lose time from activities of 
daily living due to repeated admissions and repeated procedures. 
Mesenchymal Stromal Cells (MSC) aims at reducing repeated hospitalizations and the 
need for repeated sittings of surgery. 
Mesenchymal Stromal Cells (MSC) has been shown to exhibit differentiation ability as 
well as immune modulatory function. In studies it has been shown that injection of 
mesenchymal stromal cells is safe and feasible with no side effect profile in the 
treatment of fistula-in-ano.  
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We recruited seven patients suffering from non-healing high crypto glandular fistula-in-
ano with failure to respond to conventional therapy (e.g. Surgery) after obtaining 
informed consent. 
At the end of the study it was found that only one patient had complete resolution of 
symptoms although radiological resolution was not demonstrated. None of the patients 
had any adverse effects following injection of Mesenchymal Stromal Cells(MSC) and was 
found to be safe. 
Six of these patients underwent examination under anaesthesia and laying open of the 
fistula tract due to recurrence of symptoms. One patient continues to have resolution of 
symptoms and is on close follow-up. 
In conclusion, the injection of heterologous mesenchymal stromal cells in the treatment 
of chronic non-healing cryptoglandular fistula-in-ano although appeared to be safe as 
none of the patients revealed any side-effects of treatment, it did not reveal any benefit 
in the healing of these fistula tracts. Since the study recruited only seven patients and 
was designed as a pilot study more research needs to be pursued using Mesenchymal 
Stromal Cells in a larger patient population. 
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Limitations 
1. Most of the patients who were recruited in the study were not from the 
local area and needed to travel long distances for follow-up which led to 
financial and logistic restraints. 
2. The procedure of procurement of Mesenchymal Stromal Cells (MSC) was 
done at a site which was a few kilometers away from the operation suite 
and thus we faced logistical challenges in transportation of the same. 
3. There were monetary limitations in processing and procuring these 
Mesenchymal Stromal Cells (MSC) as well as preoperative and post-
operative MRI scans. 
4. This study was done as a pilot study on a small patient population and 
needs to carried out on a larger scale. 
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INFORMED CONSENT 
Christian Medical College, Vellore 
Department of General Surgery Unit IV 
 
A pilot study to determine the feasability safety and efficacy of injection of 
heterogenous Mesenchymal Stromal Cells (MSC) in the treatment of recurrent high 
cryptoglandular fistula-in-ano 
 
Information sheet 
Patient Information Sheet. 
Your doctor has informed you that you have a recurrent nonhealing fistula in ano which 
is unlikely to heal in the usual way by itself. He has also told you that there is a new 
method of treatment being evaluated which involves injecting Mesenchymal stromal 
cells around the fistulous tracts which is to help in closing of the fistulas. You are invited 
to take part in this study, but before you do so, it is important for you to understand 
why this research is being done and what would happen if you are involved. Please read 
the information below and do not hesitate to ask any questions. 
 
What is a recurrent fistula? 
A recurrent fistula is an abnormal connection of the gastrointestinal tract to the external 
skin which has failed to respond to current method of management(Medical or Surgical) 
and is chronically discharging pus. 
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What are Mesenchymal Stromal cells? 
These cells are found in various parts of the body such as the bone marrow or placenta. 
The special characteristics of this cell type is that it can change into virtually any type of 
cell the body needs. In this study we will be injecting these cells around the fistula tract 
and assessing the degree of healing. 
What is the purpose of this study? 
In order to see whether the injection of these cells help in the healing of recurrent 
fistulas which have not responded to medical or surgical therapy. 
Why are you chosen and do you have to take part? 
You have been chosen because you have a recurrent fistula in ano that has not 
responded to Medical/Surgical treatment. If you decide to take part, you will be asked 
to sign a consent form. If you do not take part, you will continue with your usual 
treatment and the care you will receive will not be affected in any way. 
What will happen if I take part? 
Once you sign the consent form you will be booked for examination under anaesthesia. 
You will be given a date to get admitted in the hospital.You will be examined under 
anaesthesia . The fistula tract may be photographed for documentation purposes. 
Haematology will provide the stem cells in vials which will be diluted to 10 cc and 
injected using a long large bore needle. 
You will be required to follow up with us in OPD after 1 week, 1 month,2 months and 1 
year. At the end of 1 month your wound shall be reviewed and if there are no signs of 
healing you shall be subject to another injection of Mesenchymal Stromal cells around 
the fistula tract in a manner as mentioned above. 
At the end of 2 months you will undergo a clinical as well as a radiological evaluation 
which includes an MRI scan of the pelvis to assess the fistula. 
No further intervention shall be done henceforth. 
You may be contacted over the phone or asked to follow up on OPD basis after the end 
of 1 year. 
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What are the side effects of taking part? 
From the available literature it appears that infusion of volunteer bone marrow derived 
MSC is safe. There can however be occasional mild reactions when the cells are infused 
(infusional toxicity) which can very rarely be life threatening. It is possible to develop an 
allergic reaction to some of the components of the infusion. 
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you but if you do develop any side effects or 
problems due to the study, these will be treated at no cost to you. We are unable to 
provide any monetary compensation, however.  
Will you have to pay for the treatment?  
The Mesenchymal stromal cells are provided by the Department of Haematology. The 
follow up MRI scan is being funded for by the fluid grant. Hence the only expenditure 
you shall incur would be the pre treatment MRI.   
Will my taking part be confidential?  
Yes. If you take part in the study, the doctors involved will look your charts and other 
documents. This study is coordinated by the Dept of General Surgery Unit IV, Christian 
Medical College, Vellore. The information about you is stored on a computer and in 
confidential charts. Noone other than the personnel in the study will have access to 
your records. 
 
What will happen to the results of the study? 
The data will be analysed. If there is a significant result, then it will change the way in 
which chronic recurrent fistula in ano are treated. 
Who has approved this study? 
This study has been cleared by the Department of General Surgery, Department of 
Haematology and the Ethics committee, Christian Medical College, Vellore. 
 
If you have any further questions, please ask Dr.Zeeshan, Dr. Manbha or Dr. Sukriya 
Nayak(tel: 0416 2282441/ 09629229239) or email: surgery4@cmcvellore.ac.in 
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CONSENT TO TAKE PART IN A CLINICAL TRIAL 
 
Study Title: A pilot study to determine whether direct injection of mesenchymal stromal 
cells into the fistula tract helps in the healing of the tract. 
Study Number:  
Participant’s name:  
Date of Birth / Age (in years): 
 
I_____________________________________________________________ 
___________, son/daughter of  ___________________________________ 
 
(Please tick boxes) 
Declare that I have read the information sheet provide to me regarding this study and 
have clarified any doubts that I had. [ ] 
I also understand that my participation in this study is entirely voluntary and that I am 
free to withdraw permission to continue to participate at any time without affecting my 
usual treatment or my legal rights [ ] 
I understand that mesenchymal cells derived from another human being after being 
processed will be injected in me and I give my consent for the same [ ] 
I understand that the study staff and institutional ethics committee members will not 
need my permission to look at my health records even if I withdraw from the trial. I 
agree to this access [ ]  
I understand that my identity will not be revealed in any information released to third 
parties or published [ ]   
I voluntarily agree to take part in this study [ ] 
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Signature:                                    Witness Signature:                      Investigator’s Signature: 
Name:                                          Name:                                         Name:            
Date:                                            Date:                                           Date: 
Place:                                           Place:                                          Place: 
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CONSENT FOR PHOTOGRAPHY 
 
I  have been explained regarding my diagnosis of recurrent fistula in ano and have 
willingly enrolled in this study of use of heterologous Mesenchymal Stromal Cells(MSC) 
serial injection into the fistula tract. 
 
I understand the need of pre procedure as well as post procedure photographs of the 
fistulous tract as well as the need for documentation of the procedure of injection of the 
stromal cells into the fistula tract. 
 
I have been explained that these photographs may be used in future publications with 
my identity fully protected and I hereby give my consent for the same. 
 
 
 
 
 
Patient signature                                                                                   Doctor’s signature 
 
 
 
